Sight Sciences Stock Performance
| SGHT Stock | USD 3.76 0.03 0.80% |
The entity has a beta of 3.37, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sight Sciences will likely underperform. At this point, Sight Sciences has a negative expected return of -0.91%. Please make sure to validate Sight Sciences' maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Sight Sciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Sight Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's technical indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 0.8 | Five Day Return (3.34) | Year To Date Return (26.27) | Ten Year Return (88.78) | All Time Return (88.78) |
1 | Acquisition by Jeremy Hayden of 12000 shares of Sight Sciences subject to Rule 16b-3 | 09/16/2024 |
2 | Disposition of 3403 shares by Sam Park of Sight Sciences at 6.08 subject to Rule 16b-3 | 10/01/2024 |
3 | Disposition of 3167 shares by Badawi David of Sight Sciences at 5.986 subject to Rule 16b-3 | 10/02/2024 |
4 | Disposition of 20734 shares by Matthew Link of Sight Sciences at 5.905 subject to Rule 16b-3 | 10/16/2024 |
5 | Sight Sciences to Report Third QuarterFinancial Results on November 7, 2024 | 10/17/2024 |
6 | Disposition of 21831 shares by Matthew Link of Sight Sciences at 5.609 subject to Rule 16b-3 | 10/21/2024 |
7 | Integer Q3 Earnings Surpass Estimates | 10/24/2024 |
8 | Acquisition by Sam Park of 6000 shares of Sight Sciences at 1.96 subject to Rule 16b-3 | 10/25/2024 |
9 | Insider Trading | 11/04/2024 |
10 | Sight Sciences Downgraded by Lake Street Capital to Hold | 11/05/2024 |
11 | Sight Sciences Inc Q3 2024 Earnings Revenue at 20.2M Misses Estimates, EPS of -0. ... | 11/07/2024 |
12 | Sight Sciences GAAP EPS of -0.22, revenue of 20.2M | 11/08/2024 |
13 | Acquisition by Manohar Raheja of 96000 shares of Sight Sciences at 4.59 subject to Rule 16b-3 | 11/12/2024 |
14 | Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference | 11/19/2024 |
| Begin Period Cash Flow | 185 M | |
| Free Cash Flow | -48 M |
Sight |
Sight Sciences Relative Risk vs. Return Landscape
If you would invest 705.00 in Sight Sciences on August 24, 2024 and sell it today you would lose (329.00) from holding Sight Sciences or give up 46.67% of portfolio value over 90 days. Sight Sciences is currently does not generate positive expected returns and assumes 3.9753% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Sight, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sight Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sight Sciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sight Sciences, and traders can use it to determine the average amount a Sight Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.23
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SGHT |
Estimated Market Risk
| 3.98 actual daily | 35 65% of assets are more volatile |
Expected Return
| -0.91 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.23 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sight Sciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sight Sciences by adding Sight Sciences to a well-diversified portfolio.
Sight Sciences Fundamentals Growth
Sight Stock prices reflect investors' perceptions of the future prospects and financial health of Sight Sciences, and Sight Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sight Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.63) % | ||||
| Operating Margin | (0.56) % | ||||
| Current Valuation | 104.71 M | ||||
| Shares Outstanding | 50.4 M | ||||
| Price To Book | 1.98 X | ||||
| Price To Sales | 2.36 X | ||||
| Revenue | 81.06 M | ||||
| Gross Profit | 58.97 M | ||||
| EBITDA | (49.41 M) | ||||
| Net Income | (55.55 M) | ||||
| Cash And Equivalents | 220.1 M | ||||
| Cash Per Share | 4.60 X | ||||
| Total Debt | 35.41 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 16.73 X | ||||
| Book Value Per Share | 1.88 X | ||||
| Cash Flow From Operations | (47.18 M) | ||||
| Earnings Per Share | (1.01) X | ||||
| Market Capitalization | 187.98 M | ||||
| Total Asset | 166.65 M | ||||
| Retained Earnings | (294.79 M) | ||||
| Working Capital | 150.62 M | ||||
About Sight Sciences Performance
Assessing Sight Sciences' fundamental ratios provides investors with valuable insights into Sight Sciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Sight Sciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 241.13 | 253.19 | |
| Return On Tangible Assets | (0.33) | (0.35) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | (0.46) | (0.44) |
Things to note about Sight Sciences performance evaluation
Checking the ongoing alerts about Sight Sciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sight Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sight Sciences generated a negative expected return over the last 90 days | |
| Sight Sciences has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 81.06 M. Net Loss for the year was (55.55 M) with profit before overhead, payroll, taxes, and interest of 58.97 M. | |
| Sight Sciences currently holds about 220.1 M in cash with (47.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.6, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sight Sciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference |
- Analyzing Sight Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sight Sciences' stock is overvalued or undervalued compared to its peers.
- Examining Sight Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sight Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sight Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sight Sciences' stock. These opinions can provide insight into Sight Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Sight Stock Analysis
When running Sight Sciences' price analysis, check to measure Sight Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sight Sciences is operating at the current time. Most of Sight Sciences' value examination focuses on studying past and present price action to predict the probability of Sight Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sight Sciences' price. Additionally, you may evaluate how the addition of Sight Sciences to your portfolios can decrease your overall portfolio volatility.